Pharmacokinetic drug-drug interactions between 1,4-dihydropyridine calcium channel blockers and statins: Factors determining interaction strength and relevant clinical risk management

Therapeutics and Clinical Risk Management

Volumn 10, Issue 1, 2014, Pages 17-26

  Zhou, Yi Ting ^a   Yu, Lu Shan ^b   Zeng, Su ^b   Huang, Yu Wen ^a   Xu, Hui Min ^a   Zhou, Quan ^a  

^a Second Affiliated Hospital   (China)

^b ZHEJIANG UNIVERSITY   (China)

Author keywords

1,4 dihydropyridine; CYP3A4; Drug drug interactions; HMG CoA reductase inhibitors; Myopathy; Physicochemical phenomena; Polypharmacy; Prescription auditing

Indexed keywords

AMLODIPINE; AMLODIPINE PLUS ATORVASTATIN; ATORVASTATIN; AZELNIDIPINE; BENIDIPINE; CALCIUM CHANNEL BLOCKING AGENT; CYTOCHROME P450 3A4; FLUINDOSTATIN; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; ISRADIPINE; LACIDIPINE; LERCANIDIPINE; MEVINOLIN; NICARDIPINE; NIMODIPINE; PRAVASTATIN; SIMVASTATIN;

AREA UNDER THE CURVE; CARDIOVASCULAR RISK; DRUG ABSORPTION; DRUG BIOAVAILABILITY; DRUG EFFICACY; DRUG HALF LIFE; DRUG MECHANISM; DRUG MEGADOSE; DRUG METABOLISM; DRUG POTENTIATION; DRUG RESPONSE; DRUG SAFETY; DRUG STABILITY; ENZYME INHIBITION; EVENING DOSAGE; FIRST PASS EFFECT; HUMAN; HYPERTENSION; LIPOPHILICITY; MAXIMUM PLASMA CONCENTRATION; MYOPATHY; NONHUMAN; PHYSICAL CHEMISTRY; PROTEIN EXPRESSION; RECOMMENDED DRUG DOSE; REVIEW; SYSTEMATIC REVIEW (TOPIC); TIME TO MAXIMUM PLASMA CONCENTRATION;

EID: 84891133782     PISSN: 11766336     EISSN: 1178203X     Source Type: Journal    
DOI: 10.2147/TCRM.S55512     Document Type: Review

References (39)

1. Corsonello A, Pedone C, Corica F, Incalzi RA. Polypharmacy in elderly patients at discharge from the acute care hospital. Ther Clin Risk Manag. 2007;3(1):197-203.
2. Koh Y, Kutty FB, Li SC. Drug-related problems in hospitalized patients on polypharmacy: the influence of age and gender. Ther Clin Risk Manag. 2005;1(1):39-48.
3. Köberlein J, Gottschall M, Czarnecki K, Thomas A, Bergmann A, Voigt K. General practitioners' views on polypharmacy and its consequences for patient health care. BMC Fam Pract. 2013;14(1):119.
4. Li W, Zeng S, Yu LS, Zhou Q. Pharmacokinetic drug interaction profile of omeprazole with adverse consequences and clinical risk management. Ther Clin Risk Manag. 2013;9:259-271.
5. Joint Commission International. Joint Commission International Accreditation Standards for Hospitals; Standards Lists Version. 4th ed. Oak Brook, IL: Joint Commission International; 2010. Available from: http://www.jointcommissioninternational.org/common/pdfs/jcia/IAS400_Standards_Lists_Only.pdf. Accessed March 20, 2013.
6. Leung A, Schaefer EW, Tempelhof MW, Stone NJ. Emphasizing statin safety in the hospitalized patient: a review. Am J Med. 2012;125(9): 845-853.
7. Henneman A, Thornby KA. Risk of hypotension with concomitant use of calcium-channel blockers and macrolide antibiotics. Am J Health Syst Pharm. 2012;69(12):1038-1043.
8. fda.gov [homepage on the Internet]. FDA drug safety communication: new restrictions, contraindications, and dose limitations for Zocor (simvastatin) to reduce the risk of muscle injury; 2011 [updated December 15, 2011; cited October 4, 2013] Available from: http://www.fda.gov/Drugs/DrugSafety/ucm256581.htm. Accessed November 17, 2013.
9. Wiwanitkit S, Wiwanitkit V. Inappropriate concomitant use of amlodipine and simvastatin: A report on its incidence in a primary care unit. Indian J Endocrinol Metab. 2011;15 Suppl 4:S409.
10. Lee CK, Choi JS, Choi DH. Effects of pravastatin on the pharmacokinetic parameters of nimodipine after oral and intravenous administration in rats: possible role of CYP3A4 inhibition by pravastatin. Indian J Pharmacol. 2012;44(5):624-628.
11. Chung JW, Yang SH, Choi JS. Effects of lovastatin on the pharmacokinetics of nicardipine in rats. Biopharm Drug Dispos. 2010;31(7): 436-441.
12. Zhou LX, Finley DK, Hassell AE, Holtzman JL. Pharmacokinetic interaction between isradipine and lovastatin in normal, female and male volunteers. J Pharmacol Exp Ther. 1995;273(1):121-127.
13. Ziviani L, Da Ros L, Squassante L, Milleri S, Cugola M, Iavarone LE. The effects of lacidipine on the steady/state plasma concentrations of simvastatin in healthy subjects. Br J Clin Pharmacol. 2001;51(2): 147-152.
14. Son H, Lee D, Lim LA, Jang SB, Roh H, Park K. Development of a Pharmacokinetic Interaction Model for Co-administration of Simvastatin and Amlodipine. Drug Metab Pharmacokinet. Epub August 20, 2013.
15. Katoh M, Nakajima M, Shimada N, Yamazaki H, Yokoi T. Inhibition of human cytochrome P450 enzymes by 1,4-dihydropyridine calcium antagonists: prediction of in vivo drug-drug interactions. Eur J Clin Pharmacol. 2000;55(11-12):843-852.
16. APO-Lercanidipine (lercanidipine hydrochloride) tablets [product information]. North Ryde: Apotex Pty Ltd; 2010.
17. Boralli VB, Coelho EB, Sampaio SA, Marques MP, Lanchote VL. Enantioselectivity in the pharmacokinetic interaction between fluvastatin and lercanidipine in healthy volunteers. J Clin Pharmacol. 2009; 49(2):205-211.
18. CADUET (amlodipine besylate/atorvastatin calcium) tablets [patient information]. New York, NY: Pfizer Inc; 2012.
19. Nimotop (nimodipine) Prescribing Information. Available from: http://www.accessdata.fda.gov/drugsatfda_docs/label/2006/018869s014lbl.pdf. Accessed October 4, 2013.
20. Liu XQ, Ren YL, Qian ZY, Wang GJ. Enzyme kinetics and inhibition of nimodipine metabolism in human liver microsomes. Acta Pharmacol Sin. 2000;21:690-694.
21. Katoh M, Nakajima M, Yamazaki H, Yokoi T. Inhibitory potencies of 1,4-dihydropyridine calcium antagonists to P-glycoprotein-mediated transport: comparison with the effects on CYP3A4. Pharm Res. 2000;17:1189-1197.
22. Motens Tablets 4mg. Prescribing Information. Available from: http://www.medicines.org.uk/emc/medicine/298/SPC. Accessed October 5, 2013.
23. ZOCOR (simvastatin) Tablets. Product Information. Available from: http://www.accessdata.fda.gov/drugsatfda_docs/label/2011/019766s077s082lbl.pdf. Accessed October 5, 2013.
24. Nishio S, Watanabe H, Kosuge K, Uchida S, Hayashi H, Ohashi K. Interaction between amlodipine and simvastatin in patients with hypercholesterolemia and hypertension. Hypertens Res. 2005; 28(3):223-227.
25. Park CG, Lee H, Choi JW, Lee SJ, Kim SH, Lim HE. Non-concurrent dosing attenuates the pharmacokinetic interaction between amlodipine and simvastatin. Int J Clin Pharmacol Ther. 2010;48(8):497-503.
26. Sugiyama Y, Mimura N, Kuwabara T, Kobayashi H, Ushiki J, Fuse E. Effect of benidipine on simvastatin metabolism in human liver microsomes. Drug Metab Pharmacokinet. 2007;22(3):199-205.
27. Chung M, Calcagni A, Glue P, Bramson C. Bioavailability of amlodipine besylate/atorvastatin calcium combination tablet. J Clin Pharmacol. 2006;46(9):1030-1037.
28. Zhou Q, Ruan ZR, Yuan H, Zeng S. CYP2C9*3(1075A.C), MDR1 G2677T/A and MDR1 C3435T are determinants of inter-subject variability in fluvastatin pharmacokinetics in healthy Chinese volunteers. Arzneimittelforschung. 2012;62(11):519-524.
29. Uesawa Y, Mohri K. Relationship between lipophilicities of 1,4-dihydropyridine derivatives and pharmacokinetic interaction strengths with grapefruit juice. Yakugaku Zasshi. 2008;128(1): 117-122.
30. Harmsze AM, Robijns K, van Werkum JW, et al. The use of amlodipine, but not of P-glycoprotein inhibiting calcium channel blockers is associated with clopidogrel poor-response. Thromb Haemost. 2010;103(5): 920-925.
31. Zhou Q, Ruan ZR, Jiang B, Yuan H, Zeng S. Simvastatin pharmacokinetics in healthy Chinese subjects and its relations with CYP2C9, CYP3A5, ABCB1, ABCG2 and SLCO1B1 polymorphisms. Pharmazie. 2013;68(2):124-128.
32. Zuo XC, Zhou YN, Zhang BK, et al. Effect of CYP3A5*3 Polymorphism on Pharmacokinetic Drug Interaction between Tacrolimus and Amlodipine. Drug Metab Pharmacokinet. 2013;28(5):398-405.
33. Walsky RL, Obach RS, Hyland R, et al. Selective mechanism-based inactivation of CYP3A4 by CYP3cide (PF-04981517) and its utility as an in vitro tool for delineating the relative roles of CYP3A4 versus CYP3A5 in the metabolism of drugs. Drug Metab Dispos. 2012;40:1686-1697.
34. Jacobson TA. Comparative pharmacokinetic interaction profiles of pravastatin, simvastatin, and atorvastatin when coadministered with cytochrome P450 inhibitors. Am J Cardiol. 2004;94(9):1140-1146.
35. Hoch M, Hoever P, Theodor R, Dingemanse J. Almorexant effects on CYP3A4 activity studied by its simultaneous and time-separated administration with simvastatin and atorvastatin. Eur J Clin Pharmacol. 2013;69(6):1235-1245.
36. Teng R, Mitchell PD, Butler KA. Pharmacokinetic interaction studies of co-administration of ticagrelor and atorvastatin or simvastatin in healthy volunteers. Eur J Clin Pharmacol. 2013;69(3):477-487.
37. Ohno Y, Hisaka A, Suzuki H. General framework for the quantitative prediction of CYP3A4-mediated oral drug interactions based on the AUC increase by coadministration of standard drugs. Clin Pharmacokinet. 2007;46(8):681-696.
38. Zhou Q, Chen QX, Ruan ZR, Yuan H, Xu HM, Zeng S. CYP2C9*3 (1075A.C), ABCB1 and SLCO1B1 genetic polymorphisms and gender are determinants of inter-subject variability in pitavastatin pharmacokinetics. Pharmazie. 2013;68(3):187-194.
39. Zhou Q, Ruan ZR, Yuan H, Xu DH, Zeng S. ABCB1 gene polymorphisms, ABCB1 haplotypes and ABCG2 c.421c.A are determinants of inter-subject variability in rosuvastatin pharmacokinetics. Pharmazie. 2013;68(2):129-134.